Company / Net Income
Abbott Laboratories Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$6.5B
FY2025
5-year range
$3.7B / $13.4B
FY2021-FY2025
Trend
-51.3%
vs FY2024
Sector context
#4 of 164
Health Care
What the data says
Among 164 Health Care companies, Abbott Laboratories is in the top 2% for net income. Net Income has fluctuated over the past 10 years, ranging from $1.4B in FY2018 to $13.4B in FY2024.
Based on SEC 10-K filings.
$6.5B in FY2025 with a 5-year CAGR of +22.5%. Top quartile in the Health Care sector.
Declined from $7.1B to $6.5B over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- +13.2%
- 5-Year CAGR
- +22.5%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 164This company $6.5B Sector average $467.5M
▼
+1295.4% above sector average
Key checks
Key Insights
- 5-year CAGR of +22.5%, indicating consistent growth.
- In FY2025, net income decreased 51.3% year-over-year.
- Ranks #4 out of 164 companies in the Health Care sector.
- Peak net income was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.5B | -51.3% |
| FY2024 | $13.4B | +89.5% |
| FY2023 | $7.1B | +57.3% |
| FY2022 | $4.5B | +21.9% |
| FY2021 | $3.7B | +55.7% |
| FY2020 | $2.4B | -35.8% |
| FY2019 | $3.7B | +163.4% |
| FY2018 | $1.4B | -68.3% |
| FY2017 | $4.4B | +93.7% |
| FY2016 | $2.3B | -11.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026